- David Eidelberg
-
David Eidelberg Nationality American Education Columbia University, Harvard Medical School Occupation Physician, Scientist Employer The Feinstein Institute for Medical Research Known for Medical Research Website [1] David Eidelberg, neurologist and scientist, is Head of the Susan & Leonard Feinstein Center for Neurosciences at The Feinstein Institute for Medical Research in Manhasset, NY and Vice Chairman for Experimental Medicine at the North Shore-LIJ Health System.[1]
Contents
Education
David Eidelberg received his B.A. from Columbia University in 1977 as class valedictorian and his M.D. from Harvard Medical School in 1981.[1] After completing residency training in neurology at Harvard, he pursued fellowship training in functional brain imaging research in London and New York.
Academic Appointments
In 1988, Dr. Eidelberg joined North Shore University Hospital in Manhasset, New York, where he established the Functional Brain Imaging Laboratory and the Movement Disorders Center. He is currently Director of the Center for Neurosciences and Susan & Leonard Feinstein Professor of Neuroscience at The Feinstein Institute for Medical Research. He is also Director of the NIH Morris K. Udall Center of Excellence for Parkinson’s Disease Research at The Feinstein Institute.
Principal Scientific Contributions
Dr. Eidelberg is internationally recognized for his pioneering work using functional imaging methods to characterize large-scale network abnormalities in brain disease. His studies were the first to identify specific changes in brain network organization in Parkinson’s disease and other movement disorders, such as dystonia, Tourette syndrome, and Huntington disease.[2][3] The characterization of distinct disease-specific metabolic networks relating to these disorders and the prospective quantification of pattern expression in individual cases have proved to be valuable for differential diagnosis and the objective assessment of disease progression and the effects of therapy. In particular, Dr. Eidelberg and his colleagues have used this approach to measure rates of network progression in preclinical carriers of the Huntington disease mutation, and in individuals with prodromal Parkinson's disease.[4] Additionally, his team was the first to demonstrate a consistent relationship between treatment-mediated network modulation in individual patients (measured using functional brain imaging) and independent descriptors of therapeutic outcome (measured using standardized clinical ratings).[5] This work set the stage for the recent introduction of functional brain networks as imaging biomarkers with which to assess novel therapies, such as gene therapy interventions for Parkinson’s disease. Eidelberg's network method has also proved useful in clarifying mechanisms of clinical penetrance in dominantly inherited neurological disorders such as primary torsion dystonia and Huntington’s disease.
Awards and Honors
- American Academy of Neurology Movement Disorders Research Award, 2010[6]
- American Parkinson Disease Association Fred Springer Award, 2005
- Scientific Advisory Board Member: Michael J. Fox Foundation, 2004-present[7]
- Scientific Advisory Board Member: Bachmann-Strauss Dystonia and Parkinson Foundation, 2009-present[8]
- Scientific Director of The Thomas Hartman Foundation for Parkinson’s Research, 2007-present[9]
- Editorial Board Member: Journal of Nuclear Medicine (1999-Present)[10], Current Opinion in Neurology (2001-Present)[11], and Annals of Neurology (2006-Present)[12]
- Associate Editor: Journal of Neuroscience (2010-Present)[13]
- Book: Imaging in Parkinson’s disease. Eidelberg D, editor. New York: Oxford University Press; 2011 [expected publication date, Aug 30, 2011]
Selected Publications
(2006-2011; Selected from a total of over 350)
- Ulug AM, Vo A, Argyelan M, Tanabe L, Schiffer WK, Dewey S, Dauer WT, Eidelberg D. Selective motor system abnormalities in DYT1 mutant TorsinA knock-in mice. Proc Natl Acad Sci USA, 2011; 108(16):6638-6643
- Carbon M, Argyelan M, Ghilardi MF, Mattis P, Dhawan V, Bressman S, Eidelberg D. Impaired sequence learning in dystonia mutation carriers: a genotypic effect. Brain, 2011; 134(Pt 5): 1416-27
- Pourfar M, Feigin A, Tang CC, Carbon-Correll M, Bussa M, Budman C, Dhawan V, Eidelberg D. Abnormal metabolic brain networks in Tourette syndrome. Neurology, 2011; 76(11):944-952
- Spetsieris PG, Eidelberg D. Scaled subprofile modeling of resting state imaging data in Parkinson’s disease: methodological issues. NeuroImage, 2011; 54:2899-2914
- Mure H, Hirano S, Tang CC, Isaias IU, Antonini A, Ma Y, Dhawan V, Eidelberg D. Parkinson’s disease tremor-related metabolic network: characterization, progression, and treatment effects. NeuroImage, 2011; 54(2):1244-53
- Ma Y, Huang C, Dyke JP, Pan H, Feigin A, Eidelberg D. Parkinson’s disease spatial covariance pattern: Non-invasive quantification with perfusion MRI. J Cereb Blood Flow Metab, 2010; 30(3):505-9
- Carbon M, Argyelan M, Habeck C, Ghilardi MF, Fitzpatrick T, Dhawan V, Pourfar M, Bressman SB, Eidelberg D. Increased sensorimotor network activity in DYT1 dystonia: A functional imaging study. Brain, 2010; 133(Pt 3):690-700
- Tang C, Poston K, Eckert T, Feigin A, Frucht S, Gudesblatt M, Dhawan V, Lesser M, Vonsattel J-P, Fahn S, Eidelberg D. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol, 2010; 9(2):149-58
- Tang C, Poston K, Dhawan V, Eidelberg D. Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson’s disease. J Neurosci, 2010; 30(3):1049-56
- Pourfar M, Tang C, Lin T, Dhawan V, Kaplitt M, Eidelberg D. Assessing the microlesion effect of subthalamic deep brain stimulation surgery with FDG PET. J Neurosurg, 2009; 110(6):1278-82
- Argyelan M, Carbon M, Niethammer M, Ulug AM, Henning UV, Bressman SB, Dhawan V, Eidelberg D. Cerebello-thalamo-cortical connectivity regulates penetrance in dystonia. J Neurosci, 2009; 29(31):9740-7
- Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci, 2009; 32(10):548-57 [Review]
- Carbon M, Niethammer M, Peng S, Raymond D, Dhawan V, Chaly T, Ma Y, Bressman S, Eidelberg D. Abnormal striatal and thalamic dopamine neurotransmission: genotype-related features of dystonia. Neurology, 2009; 72(24):2097-103
- Argyelan M, Carbon M, Ghilardi MF, Feigin A, Mattis P, Dhawan V, Eidelberg D. Dopaminergic suppression of brain deactivation responses during sequence learning. J Neurosci, 2008; 28(42):10687-95
- Lin T, Carbon M, Tang C, Mogilner A, Sterio D, Beric A, Dhawan V, Eidelberg D. Metabolic correlates of subthalamic nucleus activity in Parkinson’s disease. Brain, 2008; 131(Pt 5):1373-80
- Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson’s disease. Neurology, 2008; 70(16 Pt 2):1470-7
- Hirano S, Asanuma K, Ma Y, Tang C, Feigin A, Dhawan V, Carbon M, Eidelberg D. Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson’s disease. J Neurosci, 2008; 28(16):4201-9
- Feigin A, Kaplitt MG, Tang C, Lin T, Dhawan V, During MJ, Eidelberg D. Modulation of metabolic brain networks following subthalamic gene therapy for Parkinson’s disease. Proc Natl Acad Sci USA 2007; 104(49):19559-64
- Carbon M, Ghilardi M-F, Argyelan M, Dhawan V, Bressman S, Eidelberg D. Increased cerebellar activation during sequence learning in DYT1 carriers: An equiperformance study. Brain 2008; 131(Pt 1):146-54.
- Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, Dhawan V, Eidelberg D. Changes in network activity with the progression of Parkinson’s disease. Brain 2007; 130(Pt 7):1834-46
- Kaplitt M, Feigin A, Tang C, Fitzsimons H, Mattis P, Lawlor P, Bland R, Young D, Strybing K, Eidelberg D†, During M†. Safety and tolerability of AAV-GAD gene therapy for Parkinson’s disease: An open label, phase I trial. Lancet 2007; 369(9579):2097-2105. [† Shared senior authorship]
- Ma Y, Tang C, Spetsieris P, Dhawan V, Eidelberg D. Abnormal metabolic network activity in Parkinson’s disease: test-retest reproducibility. J Cereb Blood Flow Metab 2007; 27(3):597-605
- Feigin A, Tang C, Ma Y, Mattis P, Zgaljardic D, Guttman M, Paulsen JS, Dhawan V, Eidelberg D. (2007) Thalamic metabolism and symptom onset in preclinical Huntington’s disease. Brain 2007; 130(Pt 11):2858-67.
- Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson’s disease. NeuroImage 2007; 34(2):714-23
- Asanuma K, Tang C, Ma Y, Dhawan V, Mattis P, Edwards C, Kaplitt MG, Feigin A, Eidelberg D. Network modulation in the treatment of Parkinson’s disease. Brain, 2006; 129(Pt 10):2667-78
References
- ^ a b "Centers of Excellence". The Feinstein Institute for Medical Research. http://www.feinsteininstitute.org/Feinstein/About+David+Eidelberg. Retrieved 3 August 2011.
- ^ "Increased sensorimotor network activity in DYT1 dystonia: A functional imaging study". Brain 133 ((Pt 3)): 690–700. 2010. doi:10.1093/brain/awq017. PMC 2842516. PMID 20207699. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2842516. Retrieved 3 August 2011.
- ^ "Abnormal metabolic brain networks in Tourette syndrome". Neurology 76 (11): 944–952. 2011. PMID 21307354.
- ^ "Parkinson’s disease tremor-related metabolic network: characterization, progression, and treatment effects". NeuroImage 54 (2): 1244–53. 2011. doi:10.1016/j.neuroimage.2010.09.028. PMC 2997135. PMID 20851193. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2997135. Retrieved 3 August 2011.
- ^ "Network modulation in the treatment of Parkinson’s disease". Brain 129 (Pt 10): 2667–78. 2006.
- ^ "Past Award Winners". American Academy of Neurology. http://www.aan.com/science/awards/index.cfm. Retrieved 3 August 2011.
- ^ "Scientific and Special Advisors". Michael J. Fox Foundation. http://www.michaeljfox.org/about_people_advisors.cfm. Retrieved 3 August 2011.
- ^ "Scientific Advisory Board". Bachmann-Strauss Dystonia and Parkinson Foundation. http://www.dystonia-parkinsons.org/index.cfm?fuseaction=home.viewPage&page_id=22784577-CB38-D9CA-E1429D8BBD27157F. Retrieved 3 August 2011.
- ^ "Striking at the Causes of Parkinson's". The Thomas Hartman Foundation for Pa rkinson's Research, Inc.. http://www.hartmanfoundation.org/pdf/thf-research-for-parkinsons.pdf. Retrieved 3 August 2011.
- ^ "Editorial Board". Journal of Nuclear Medicine. http://jnm.snmjournals.org/site/misc/edboard.xhtml. Retrieved 3 August 2011.
- ^ "Editorial Board". Current Opinion in Neurology. http://journals.lww.com/co-neurology/pages/editorialboard.aspx. Retrieved 3 August 2011.
- ^ "Editorial Board". Annals of Neurology. http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1531-8249/homepage/EditorialBoard.html. Retrieved 3 August 2011.
- ^ "About The Journal of Neuroscience". The Journal of Neuroscience. http://www.jneurosci.org/site/misc/about.xhtml#ed. Retrieved 3 August 2011.
Categories:- Parkinson's disease
- Living people
- Neurologists
Wikimedia Foundation. 2010.